arrow
S

Sumati Gupta

university of utah
H指数:28
被引数:3,545

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis

局部前列腺癌中胰岛素通路的变化:一项多中心分析

Cancers
IF4.4
2026-05-190
OA
Response to: Comment on Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)

回复:关于Nivolumab辅助化疗放疗在局部肌肉浸润性尿路上皮癌中的应用:一项多中心、单臂、II期、研究者发起试验(NEXT)的主要分析

2025-05-260
OA
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

Nivolumab联合relatlimab和nivolumab联合ipilimumab治疗晚期肾细胞癌患者: 开放标签,随机,II期分次RCC试验的结果

2024-12-010
PRE
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer
2024-06-050
PRE
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinumbased chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

TROPHY-U-01,sacituzumab govitecan用于铂化疗和检查点抑制剂后进展的转移性尿路上皮癌患者的II期开放标签研究: 更新的安全性和有效性结果

2024-04-0117
OAAI
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
2023-10-315
OAAI
Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
2023-10-010
PRE
Germline and somatic genomic profiling of urothelial carcinoma
2023-04-040
PRE